The Filing Desk

Agenus vs Atara Biotherapeutics

Agenus AGEN · Atara Biotherapeutics ATRA · Biotechnology

Atara Biotherapeutics reported revenue of $121 million in fiscal 2025, about the same as Agenus' $114 million in fiscal 2025. Agenus' revenue grew 10.4% in its latest year, and Atara Biotherapeutics' fell 6.3%. Agenus had an operating margin of -17.7%, against 29.7% at Atara Biotherapeutics. Free cash flow was −$77 million at Agenus and −$51 million at Atara Biotherapeutics.

Side by side

AgenusAtara Biotherapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$114M$121M
Revenue growth10.4%−6.3%
Revenue growth a year, last 5 years5.3%—
Gross margin99.1%—
Operating margin−17.7%29.7%
Net margin−2.7%27.1%
Free cash flow−$77M−$51M
Free cash flow margin−67.6%−42.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count38.5%69.8%
Last close$6.14$6.34
P/E at the last close——
Insider trades, last 12 months—bought $5.7 million, sold $3.8 million
Piotroski F-score3 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AgenusAtara Biotherapeutics
Operating margin
Percent of revenue
AgenusAtara Biotherapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AgenusAtara Biotherapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Agenus and Atara Biotherapeutics pages.